That's a really tough road — going through DA-EPOCH, then CAR T therapy, and now seeing new disease on the PET scan. It's completely understandable to be looking for what comes next.
For relapsed or refractory DLBCL with CNS involvement after CAR T therapy, clinical trials are often the most promising path forward Show Full Answer
That's a really tough road — going through DA-EPOCH, then CAR T therapy, and now seeing new disease on the PET scan. It's completely understandable to be looking for what comes next.
For relapsed or refractory DLBCL with CNS involvement after CAR T therapy, clinical trials are often the most promising path forward. Researchers are actively exploring several approaches, including:
- Bispecific antibodies — these help your immune system target lymphoma cells in a different way than CAR T
- New immunotherapy combinations
- Targeted therapies based on the genetic makeup of the lymphoma
- Novel CNS-directed treatments, since CNS lymphoma has unique challenges The best step right now is to speak directly with your oncologist about clinical trial eligibility. You can also search clinicaltrials.gov for trials specifically targeting relapsed DLBCL with CNS involvement post-CAR T.
Given the complexity of this situation, seeking a second opinion at a major cancer center that specializes in lymphoma is strongly worth considering. They often have access to trials not available elsewhere.
May 12
Join
Your Privacy Choices
